A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-SITE TRIAL OF THE ALPHA-2-ADRENERGIC AGONIST, LOFEXIDINE, FOR OPIOID WITHDRAWAL
Gespeichert in:
YU, E., ET AL., A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-SITE TRIAL OF THE ALPHA-2-ADRENERGIC AGONIST, LOFEXIDINE, FOR OPIOID WITHDRAWAL. DRUG AND ALCOHOL DEPENDENCE, Vol. 97, no. 1-2 (2008), p. 158-168.
Ref.
156558
Standort:
SIIS R.854 Archivo
Palabras clave:
Ceguera, Datos epidemiológicos, Drogodependencias, Estudio comparativo, Fármacos, Heroína, Programas de mantenimiento, Resultados, Tratamiento, Validez
Ceguera, Datos epidemiológicos, Drogodependencias, Estudio comparativo, Fármacos, Heroína, Programas de mantenimiento, Resultados, Tratamiento, Validez
Ähnliche Einträge: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-SITE TRIAL OF THE ALPHA-2-ADRENERGIC AGONIST, LOFEXIDINE, FOR OPIOID WITHDRAWAL
- Alpha2-adrenergic agonists for the management of opioid withdrawal (Review)
- DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL OF LOFEXIDINE VERSUS CLONIDINE IN THE TREATMENT OF HEROIN WITHDRAWAL
- RANDOMISED DOUBLE-BLIND COMPARISON OF LOFEXIDINE AND METHADONE IN THE IN-PATIENT TREATMENT OF OPIATE WITHDRAWAL
- ADRENERGIC AGONISTS IN OPIOID WITHDRAWAL
- RANDOMISED DOUBLE-BLIND COMPARISON OF LOFEXIDINE AND CLONIDINE IN THE OUT-PATIENT TREATMENT OF OPIATE WITHDRAWAL
- THE EFFECTIVENESS OF COMBINED NALOXONE/LOFEXIDINE IN OPIATE DETOXIFICATION. RESULTS FROM A DOUBLE-BLIND RANDOMIZED AND PLACEBO-CONTROLLED TRIAL